Clinic
Baptist Memorial Hospital-Desoto, INC,
Baptist Memorial Hospital-Desoto, INC, was paid $41.70M by Medicaid between Jan 2018 and Dec 2024, across 307 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoBAPTIST MEMORIAL HOSPITAL-DESOTO, INC,
SOUTHAVEN, MS 38671
SOUTHAVEN, MS 38671
33aNPI1194789818assigned 04/12/2006
33bProvider typeMulti-Specialty Clinic/Center
28Total paid$41.70M
24GClaims1,258,614
24DCodes billed307
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Multi-Specialty Clinic/Center providers in Mississippi
Rank by total paid#2 of 18
Median peer was paid$46K
This provider vs. median911×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DUCKETT, GREGORY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 195,742 | $6.82M | |
| 2019 | 179,315 | $6.93M | |
| 2020 | 178,655 | $5.70M | |
| 2021 | 218,568 | $6.26M | |
| 2022 | 210,571 | $6.20M | |
| 2023 | 174,610 | $5.86M | |
| 2024incomplete | 101,153 | $3.93M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 42,564 | 34,260 | $7.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 30,404 | 23,947 | $5.73M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.5% | 27,482 | 23,244 | $3.53M |
| G0378 | Hospital observation service, per hour | 7.4% | 9,238 | 5,724 | $3.07M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.7% | 20,422 | 15,712 | $1.53M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.8% | 7,949 | 6,760 | $1.17M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.7% | 3,357 | 2,864 | $1.14M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 7,368 | 6,011 | $999K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 27,204 | 16,596 | $769K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 13,578 | 7,807 | $758K |
| D0272 | Bitewings - two radiographic images | 1.7% | 1,127 | 946 | $718K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 20,633 | 16,147 | $635K |
295 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 8,194 | $599K |
| D2930 | Prefabricated stainless steel crown - primary tooth | 1.4% | 11,944 | $598K |
| D7140 | Extraction, erupted tooth or exposed root | 1.4% | 1,851 | $585K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.4% | 4,841 | $577K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 6,652 | $554K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.3% | 7,687 | $546K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 29,032 | $518K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 21,101 | $483K |
| 80053 | Comprehensive metabolic panel | 1.1% | 76,640 | $479K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.0% | 14,831 | $417K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 8,981 | $388K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,121 | $372K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 26,977 | $354K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 69,944 | $313K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 27,613 | $297K |
| 93017 | <1% | 3,979 | $284K | |
| 86900 | <1% | 5,843 | $266K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,139 | $234K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,807 | $224K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,923 | $223K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,395 | $217K |
| 36415 | Collection of venous blood by venipuncture | <1% | 98,641 | $203K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,155 | $200K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,998 | $189K |
| 84484 | <1% | 27,169 | $180K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,628 | $179K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,849 | $175K |
| J0897 | Injection, denosumab, 1 mg | <1% | 314 | $171K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,110 | $154K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,931 | $133K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,008 | $129K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,997 | $128K |
| D2934 | <1% | 2,506 | $111K | |
| 86850 | <1% | 5,179 | $109K | |
| 83880 | <1% | 5,562 | $108K | |
| 72100 | <1% | 2,150 | $106K | |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 3,122 | $104K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,204 | $88K |
| 93880 | <1% | 1,498 | $87K | |
| 86901 | <1% | 6,029 | $85K | |
| 73560 | <1% | 2,525 | $83K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,045 | $82K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,309 | $82K |
| 81001 | <1% | 34,753 | $80K | |
| 74018 | <1% | 1,946 | $79K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,358 | $75K |
| 83735 | <1% | 21,039 | $74K | |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 43 | $73K |
| 85027 | <1% | 21,752 | $70K | |
| 71250 | <1% | 2,151 | $69K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,538 | $69K |
| 93971 | <1% | 1,974 | $68K | |
| 93458 | <1% | 58 | $66K | |
| 73030 | <1% | 1,990 | $64K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,058 | $58K |
| D3320 | <1% | 135 | $58K | |
| 76830 | Ultrasound, transvaginal | <1% | 917 | $57K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 865 | $57K |
| 81025 | <1% | 8,669 | $56K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,984 | $53K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 7,297 | $53K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,615 | $52K |
| 73610 | <1% | 1,323 | $51K | |
| 73630 | <1% | 1,396 | $51K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,405 | $50K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,929 | $50K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,930 | $49K |
| 36430 | <1% | 529 | $47K | |
| 83690 | <1% | 10,576 | $47K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,899 | $47K |
| 76642 | <1% | 1,460 | $46K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 143 | $45K |
| 96367 | <1% | 1,766 | $44K | |
| 84702 | <1% | 4,307 | $44K | |
| 83605 | <1% | 7,287 | $42K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,726 | $41K |
| 84703 | <1% | 8,050 | $40K | |
| 73130 | <1% | 998 | $38K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,705 | $36K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 569 | $33K |
| D2330 | <1% | 1,689 | $33K | |
| Q3014 | Telehealth originating site facility fee | <1% | 2,385 | $33K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 72 | $32K |
| 87040 | <1% | 6,096 | $32K | |
| 73502 | <1% | 1,135 | $31K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 776 | $30K |
| 93970 | <1% | 401 | $27K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 12,639 | $27K |
| 87807 | <1% | 2,495 | $27K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 233 | $27K |
| D1120 | Dental cleaning, child | <1% | 2,491 | $25K |
| 59025 | Fetal non-stress test | <1% | 258 | $25K |
| 85379 | <1% | 4,339 | $23K | |
| 77065 | Tomosynthesis, mammo | <1% | 599 | $23K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 766 | $23K |
| 73110 | <1% | 578 | $22K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 164 | $21K |
| 85610 | <1% | 9,921 | $21K | |
| 72050 | <1% | 415 | $21K | |
| 70486 | <1% | 368 | $19K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 300 | $18K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 272 | $17K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 172 | $16K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 102 | $16K |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 2,488 | $16K |
| 86923 | <1% | 424 | $16K | |
| 85730 | <1% | 4,957 | $15K | |
| 80061 | Lipid panel | <1% | 2,188 | $15K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,034 | $14K |
| 70498 | <1% | 280 | $13K | |
| 95811 | <1% | 30 | $13K | |
| 82565 | <1% | 5,395 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,360 | $12K |
| 82728 | <1% | 2,703 | $12K | |
| 70496 | <1% | 206 | $11K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 614 | $11K |
| 93925 | <1% | 150 | $10K | |
| 76770 | <1% | 200 | $10K | |
| 97162 | <1% | 587 | $10K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 19,331 | $9K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 150 | $9K |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 534 | $9K |
| 85007 | <1% | 3,638 | $8K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 152 | $8K |
| 97161 | <1% | 394 | $8K | |
| 96417 | <1% | 192 | $7K | |
| 84439 | <1% | 1,598 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 474 | $7K |
| 86140 | <1% | 2,416 | $7K | |
| 93290 | <1% | 921 | $7K | |
| 73070 | <1% | 177 | $7K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 113 | $6K |
| 93016 | <1% | 962 | $6K | |
| 83550 | <1% | 2,440 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 264 | $5K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 23 | $5K |
| 87210 | <1% | 1,449 | $5K | |
| 12011 | <1% | 59 | $5K | |
| 74022 | <1% | 78 | $5K | |
| 82607 | <1% | 891 | $4K | |
| 73590 | <1% | 107 | $4K | |
| 83540 | <1% | 2,500 | $4K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 13 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 256 | $4K |
| 93280 | <1% | 475 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,235 | $4K |
| 83615 | <1% | 1,370 | $4K | |
| 74174 | <1% | 43 | $4K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 261 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,099 | $3K |
| A9270 | Non-covered item or service | <1% | 9,999 | $3K |
| 76801 | <1% | 49 | $3K | |
| 82570 | <1% | 1,087 | $3K | |
| 82803 | <1% | 256 | $3K | |
| 73090 | <1% | 73 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,049 | $3K |
| 74019 | <1% | 111 | $3K | |
| 82550 | <1% | 748 | $3K | |
| 72070 | <1% | 65 | $3K | |
| 12001 | <1% | 29 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,473 | $3K |
| 85652 | <1% | 1,620 | $3K | |
| 82746 | <1% | 612 | $3K | |
| 85045 | <1% | 938 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,550 | $2K |
| 84550 | <1% | 917 | $2K | |
| 84100 | <1% | 1,546 | $2K | |
| 84156 | <1% | 1,019 | $2K | |
| 93018 | <1% | 962 | $2K | |
| 77336 | <1% | 37 | $2K | |
| 80069 | <1% | 475 | $2K | |
| 97166 | <1% | 52 | $1K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 1,059 | $1K |
| 86308 | <1% | 158 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12,150 | $1K |
| 72131 | <1% | 46 | $1K | |
| 97165 | <1% | 70 | $1K | |
| 73552 | <1% | 33 | $1K | |
| 85014 | <1% | 663 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 7,266 | $1K |
| 75574 | <1% | 13 | $959.45 | |
| 82150 | <1% | 177 | $917.80 | |
| 36600 | <1% | 30 | $870.37 | |
| C1769 | Guide wire | <1% | 1,581 | $839.51 |
| 82731 | <1% | 16 | $826.33 | |
| 85018 | <1% | 513 | $821.66 | |
| 96411 | <1% | 23 | $815.09 | |
| 71271 | <1% | 13 | $769.69 | |
| 87070 | <1% | 107 | $726.14 | |
| 70360 | <1% | 15 | $698.68 | |
| D0220 | Intraoral - periapical first radiographic image | <1% | 1,121 | $672.56 |
| 83970 | <1% | 46 | $671.96 | |
| 90686 | <1% | 96 | $598.51 | |
| 93289 | <1% | 58 | $590.88 | |
| 87205 | <1% | 177 | $586.77 | |
| 96376 | <1% | 8,685 | $566.01 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 4,694 | $487.10 |
| 85347 | <1% | 87 | $480.98 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,975 | $477.72 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,371 | $471.57 |
| 93283 | <1% | 51 | $470.70 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,598 | $454.05 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,382 | $446.91 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,915 | $398.19 |
| 82248 | <1% | 89 | $387.81 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,605 | $338.24 |
| 0002A | <1% | 14 | $327.31 | |
| D1351 | Sealant - per tooth | <1% | 66 | $316.89 |
| 87641 | <1% | 18 | $301.89 | |
| 84132 | <1% | 176 | $287.33 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14 | $273.98 |
| 82375 | <1% | 30 | $271.53 | |
| 73060 | <1% | 16 | $262.39 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,216 | $223.38 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 577 | $221.46 |
| 84165 | <1% | 106 | $196.62 | |
| 80047 | <1% | 45 | $193.82 | |
| 93282 | <1% | 12 | $182.66 | |
| 0001A | <1% | 20 | $180.80 | |
| 84145 | <1% | 1,429 | $166.02 | |
| 83050 | <1% | 30 | $162.65 | |
| 83655 | <1% | 14 | $154.25 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,329 | $150.81 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 3,006 | $145.31 |
| 87640 | <1% | 18 | $140.36 | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,875 | $140.13 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 757 | $134.19 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 2,143 | $129.83 |
| 93288 | <1% | 12 | $127.48 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 186 | $116.21 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 265 | $115.11 |
| 90715 | <1% | 202 | $103.59 | |
| 82010 | <1% | 21 | $74.06 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 144 | $64.55 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 3,366 | $57.34 |
| 82247 | <1% | 14 | $54.73 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,569 | $46.68 |
| D1206 | Topical application of fluoride varnish | <1% | 17 | $39.53 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 147 | $36.61 |
| 82270 | <1% | 13 | $32.50 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,538 | $32.37 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 695 | $29.40 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 603 | $26.12 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 4,801 | $24.13 |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 38 | $23.93 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,911 | $21.82 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,665 | $20.38 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,159 | $15.65 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 51 | $10.75 |
| 96368 | <1% | 21 | $10.72 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,799 | $9.63 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 69 | $9.08 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 124 | $8.69 |
| 83521 | <1% | 89 | $6.90 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 38 | $6.20 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,426 | $1.89 |
| G0008 | Administration of influenza virus vaccine | <1% | 77 | $1.13 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,552 | $0.79 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 32 | $0.23 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 72 | $0.16 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 200 | $0.05 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 265 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 382 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 59 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 271 | $0.00 |
| 76937 | 0% | 76 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 91 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 12 | $0.00 |
| Q9956 | Injection, octafluoropropane microspheres, per ml | 0% | 20 | $0.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 58 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 71 | $0.00 |
| 99204 | Doctor's office visit, new patient (more involved) | 0% | 14 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 89 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 12 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 58 | $0.00 |
| 84112 | 0% | 14 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 878 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 486 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 22 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 168 | $0.00 |
| 36416 | 0% | 333 | $0.00 | |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | 0% | 13 | $0.00 |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | 0% | 408 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 497 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 560 | $0.00 |
| 36591 | 0% | 27 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 186 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 53 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 61 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 83 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 84 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 39 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 18 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 23 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUCKETT, GREGORY (SR VP/ CLO)
Parent organizationBAPTIST MEMORIAL HEALTH CARE CORP.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.